Physician profile
Michael Eng
NPI 1710090410
$5,888.18
in general payments reported to CMS, 2019-2025
28 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $433 · 2021: $826 · 2022: $1,530 · 2023: $1,144 · 2024: $883 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,214.53 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Qol Medical, LLC | $655.00 | 2021-2025 | Sucraid, Sucraid |
| Abbvie INC. | $564.61 | 2019-2025 | |
| Braintree Laboratories, INC. | $280.81 | 2019-2023 | Suflave |
| Celgene Corporation | $268.16 | 2021-2024 | Zeposia |
| Genzyme Corporation | $220.86 | 2023 | |
| Ferring Pharmaceuticals INC. | $184.04 | 2019-2022 | |
| Stryker Corporation | $174.35 | 2023 | Axsos, Variax, Augment Injectable |
| Napo Pharmaceuticals INC | $173.03 | 2019-2022 | |
| Agile Therapeutics, INC. | $145.56 | 2021-2024 | Twirla |
| Daiichi Sankyo INC. | $125.57 | 2020-2022 | |
| Ardelyx, INC. | $116.50 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $84.34 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Avion Pharmaceuticals | $82.85 | 2020-2022 | |
| Pfizer INC. | $82.56 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.19 | 2021-2022 | |
| Shield Therapeutics INC | $60.77 | 2023 | Accrufer |
| Regeneron Healthcare Solutions, INC. | $53.85 | 2024-2025 | Dupixent |
| Evofem Biosciences, INC. | $45.13 | 2024-2025 | Solosec, Phexx, Phexxi |
| Myovant Sciences INC. | $43.80 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $40.82 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $40.65 | 2024-2025 | Voquezna |
| Medtronic, INC. | $40.00 | 2022 | |
| Millicent US INC | $36.78 | 2019-2025 | Femlyv |
| Romark Laboratories, Lc | $29.56 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2019 | |
| Celltrion USA INC. | $20.37 | 2024 | Vegzelma |
| Capsovision, INC. | $19.98 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.